Ⅰ期食管癌内镜治疗与食管切除术的回顾性队列研究:少即是多
该回顾性队列研究利用SEER数据库2004至2015年数据,纳入2133例淋巴结阴性、浅表(T1a/T1b)食管癌患者,比较内镜治疗(ET)与食管切除术的肿瘤特异性生存。调整竞争风险模型后,ET组肿瘤特异性生存优于手术组(SHR 1.92,95%CI 1.35-2.74,P<.001),且2009年后优势更明显。
要点
- Ⅰ期浅表食管癌中,ET与更优的肿瘤特异性生存相关。
- 调整后手术组肿瘤特异性死亡风险是ET组的1.92倍(SHR 1.92)。
- 2009年后ET的生存优势更显著(SHR 2.02),或与操作经验积累相关。
核心结论
- 在Ⅰ期食管癌中,内镜治疗与食管切除术相比,与改善的肿瘤特异性生存相关。
- 该优势在2009年后治疗的患者中更为明显,可能与内镜操作经验增加和患者选择优化有关。
研究设计与样本
- 回顾性队列研究,使用SEER数据库2004至2015年数据。
- 纳入2133例淋巴结阴性、浅表(T1a/T1b)食管癌患者,其中772例(36.2%)接受ET,1361例(63.8%)接受食管切除术。
- 采用竞争风险模型比较肿瘤特异性生存,Cox比例风险模型评估总生存,并按2004-2009年和2010-2015年进行亚组分析。
主要发现
- 未调整的5年肿瘤特异性生存率:ET组87.7%(95%CI 84.2-90.5),手术组82.4%(95%CI 80.0-84.5),P=.002。
- 调整竞争风险模型后,手术组肿瘤特异性生存劣于ET组(SHR 1.92;95%CI 1.35-2.74;P<.001)。
- 2004-2009年亚组:手术组SHR 1.68(95%CI 1.07-2.66;P=.024)。
- 2010-2015年亚组:手术组SHR 2.02(95%CI 1.08-3.76;P=.027)。
临床怎么用
- 对于淋巴结阴性、浅表(T1a/T1b)食管癌,内镜治疗可作为与食管切除术相当的选项,且肿瘤特异性生存可能更优。
- 临床决策时可结合患者分期、合并症及内镜治疗可及性,个体化选择内镜治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Current guidelines recommend consideration of endoscopic therapy (ET) when treating select stage I esophageal cancers. The proportion of esophageal cancers treated with ET compared with esophagectomy has increased over time. Overall and cancer-specific survival have not been shown to be superior with ET in prior population-based studies. We thus evaluated cancer-specific survival comparing patients treated with ET and esophagectomy. METHODS: We performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results database from 2004 to 2015 of patients with node-negative, superficial (T1a/T1b), esophageal cancer treated with ET or esophagectomy. Competing-risks models were used to compare cancer-specific survival. Cox proportional hazards models were used to assess overall survival. Subgroup analysis was performed comparing time periods 2004 to 2009 and 2010 to 2015. RESULTS: Of 2133 included individuals, 772 (36.2%) underwent ET and 1361 (63.8%) underwent esophagectomy. Unadjusted 5-year survival for cancer-specific death was 87.7% (95% confidence interval [CI], 84.2-90.5) for ET and 82.4% (95% CI, 80.0- 84.5) for esophagectomy (P = .002). Within the adjusted competing-risk model, cancer-specific survival was superior in patients treated with ET compared with esophagectomy (subdistribution hazard ratio [SHR], 1.92; 95% CI, 1.35-2.74; P < .001). From 2004 to 2009, the SHR for esophagectomy was 1.68 (95% CI, 1.07-2.66; P = .024); whereas from 2010 to 2015, the SHR for esophagectomy was 2.02 (95% CI, 1.08-3.76; P = .027). CONCLUSIONS: ET was associated with improved cancer-specific survival compared with esophagectomy in stage I esophageal cancer. This advantage was more pronounced for patients treated after 2009, potentially because of increasing clinician expertise in performing ET and patient selection.
引用
- McCarty JC, Parker RK, Vidri RJ, et al. A retrospective cohort study of endoscopic therapy and esophagectomy for stage 1 esophageal cancer: less is more. Gastrointest Endosc. 2020. PMID: 32276764. doi:10.1016/j.gie.2020.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。